Merkel cell carcinoma clinical trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For Merkel cell carcinoma patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

Below is a list of Merkel cell carcinoma clinical trials that are currently open and accepting patients at SCCA.
For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 11 of 11 trials

Start new search

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

ATTAC-MCC: Phase I/II study of Autologous CD8+ and CD4+ Transgenic T cells expressing high affinity MCPyV-specific TCRs combined with Avelumab and Class I MHC -upregulation in patients with metastatic MCC refractory to PD-1 axis blockade

Investigator:

Kelly Paulson, MD, PhD

Study ID:

NCT03747484

View Trial

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma

INCMGA 0012-201 A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

Investigator:

Shailender Bhatia, MD

Study ID:

NCT03599713

View Trial

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

A Phase II basket study of the oral selective pan-FGFR inhibitor Debio 1347 in subjects with solid tumors harboring a fusion of FGFR1, FGFR2 or FGFR3

Investigator:

Petros Grivas, MD, PhD

Study ID:

NCT03834220

View Trial

A Phase 1, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors with a Specific KRAS Mutation

Investigator:

Andrew Coveler, MD

Study ID:

NCT03600883

View Trial

Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors

Investigator:

Christina S. Baik, MD, MPH

Study ID:

NCT03037385

View Trial

A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Investigator:

Kaylyn Kit Man M. Wong, MD

Study ID:

NCT03289962

View Trial

Adjuvant Avelumab in Merkel Cell Cancer (ADAM)

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases

Investigator:

Shailender Bhatia, MD

Study ID:

NCT03271372

View Trial

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

A Phase 1/1b Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15-15Ra)) alone and in Combination with PDR001 in Adults with Metastatic Cancers

Investigator:

John A. Thompson, MD

Study ID:

NCT02452268

View Trial

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Investigator:

John A. Thompson, MD

Study ID:

NCT02890368

View Trial

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

Investigator:

E. Gabriela Chiorean, MD

Study ID:

NCT02667873

View Trial

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Investigator:

E. Gabriela Chiorean, MD

Study ID:

NCT02568267

View Trial